Burosumab
Crysvita is an antibody for a rare bone-softening condition in which the body leaks phosphate. Some small tumours cause it by making too much of a hormone called FGF23; when the tumour cannot be found or removed, Crysvita blocks the hormone.
Overview
Burosumab (Crysvita) has been authorised in the EU since 19 February 2018 (CHMP opinion 14 December 2017; marketing authorisation holder Kyowa Kirin Holdings B.V.; orphan designation) for X-linked hypophosphataemia in children and adolescents aged 1 to 17 with radiographic bone disease and in adults, and for FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised. The cancer-care indication is the second: it treats the metabolic effect of a tumour rather than the tumour itself.
Antibody to fibroblast growth factor 23; used for FGF23-related hypophosphataemia, including the form caused by phosphate-wasting tumours (tumour-induced osteomalacia), where the tumour cannot be found or removed (indication wording, EMA).
1.Burosumab binds its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| EU | 2018 | X-linked hypophosphataemia; FGF23-related hypophosphataemia in tumour-induced osteomalacia (phosphaturic mesenchymal tumours not curatively resectable or localisable) · Authorised 19 Feb 2018; Kyowa Kirin |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Burosumab" OR ABSTRACT:"Burosumab" OR TITLE:"Crysvita" OR ABSTRACT:"Crysvita" OR TITLE:"burosumab" OR ABSTRACT:"burosumab" OR TITLE:"KRN23" OR ABSTRACT:"KRN23") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Burosumab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentEpoetin theta
Shares the tags ema-register, supportive.
- TreatmentFentanyl (transmucosal, for breakthrough cancer pain)
Shares the tags ema-register, supportive.
- TreatmentHuman normal immunoglobulin (IVIg)
Shares the tags ema-register, supportive.